
A
beatAML
CCLE
multiomics
panel
Venetoclax
Lenvatinib
Ponatinib
Trametinib
Axitinib
I−BET−762
ACY−1215
(5Z)−7−OXOZEAENOL
METHOTREXATE
SB−590885
Improvement
0.25
0.00
−0.25


B
R = 0.4, p = 2.3e−16
% of gene expression features among top 100 Features
Mean improvement = 0.05
Multiomics improvement (CCLE)
Rsquared


C
Drug mechanism of action
HDAC inhibitor
topoisomerase inhibitor
bromodomain inhibitor
EGFR inhibitor
CDK inhibitor
mTOR inhibitor
PI3K inhibitor
AKT inhibitor
Mean Improvement (CCLE,Rsquared)


D
multiomics
panel
PDX
Drugs
llm871
lka136
ljm716
lee011
hdm201
clr457
cgm097
byl719−ljm716
byl719
bkm120
binimetinib
bgj398
Rsquared